Physician profile
William G Cataldi
NPI 1245222801
$747.87
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $18.54 · 2022: $112 · 2023: $78.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $165.95 | 2019-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $136.06 | 2019 | |
| Abbvie INC. | $62.45 | 2022-2023 | Ubrelvy, Qulipta |
| Allergan, INC. | $53.47 | 2019 | |
| Janssen Pharmaceuticals, INC | $50.51 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.36 | 2019 | |
| Merck Sharp & Dohme LLC | $47.09 | 2019 | |
| Novo Nordisk INC | $31.14 | 2019 | |
| Pfizer INC. | $24.12 | 2019 | |
| Bausch Health US, LLC | $21.83 | 2019 | |
| Dexcom, INC. | $17.41 | 2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.33 | 2019 | |
| Lilly USA, LLC | $13.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.37 | 2019 | |
| Neos Therapeutics, LP | $11.96 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $11.50 | 2019 | |
| Eisai INC. | $11.27 | 2019 | |
| Medtronic Minimed, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cataldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.